Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: A phase I trial

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Lin, Qiang ^a   Liu, Yue E ^a   Ren, Xiao Cang ^a   Wang, Na ^a   Chen, Xue Ji ^a   Wang, Dong Ying ^a   Zong, Jie ^a   Peng, Yu ^a   Guo, Zhi Jun ^a   Hu, Jing ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Accelerated hypofractionated radiotherapy; Carboplatin; Concurrent chemoradiotherapy; Maximum tolerated dose; Non small cell lung cancer; Three dimensional conformal radiotherapy; Vinorelbine

Indexed keywords

CARBOPLATIN; NAVELBINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; RADIATION ATTENUATION; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; SHORT COURSE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; VINBLASTINE;

EID: 84881516843     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-201     Document Type: Article

References (37)

1. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012, 17:682-693. 10.1634/theoncologist.2012-0020, 3360908, 22531360.
2. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215. 10.1093/jnci/88.17.1210, 8780630.
3. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
4. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98. 10.1016/j.lungcan.2004.03.004, 15364136.
5. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-90. 10.1200/JCO.2009.26.2543, 20351327.
6. Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010, 77:367-372. 10.1016/j.ijrobp.2009.04.029, 2869096, 20457350.
7. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65:1106-1111. 10.1016/j.ijrobp.2006.02.046, 16730134.
8. Bradley JD, Paulus R, Komaki R. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy cetuximab for stage IIIa/IIIb non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617 2011, Miami Beach, Florida: Presented at the 53rd ASTRO Annual Meeting.
9. Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 49:23-33. 10.1016/S0360-3016(00)01374-2, 11163494.
10. Nakayama H, Satoh H, Kurishima K, Ishikawa H, Tokuuye K. High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2010, 78:645-650. 10.1016/j.ijrobp.2009.08.037, 20869582.
11. Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012, 82:425-434. 10.1016/j.ijrobp.2010.09.004, 20980108.
12. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997, 350:161-165. 10.1016/S0140-6736(97)06305-8, 9250182.
13. Mehta MP, Tannehill SP, Adak S, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 1998, 16:3518-3523.
14. Xie SX, Li WX, Lin YR, Zou WC. Three-dimensional conformal hypofractionated radiotherapy for non-small -cell lung cancer. China Oncology 2006, 12:1034-1037. in Chinese.
15. Kim B, Ahn YC, Lim do H, Nam HR. High-dose thoracic radiation therapy at 3.0 Gy/fraction in inoperable stage I/II non-small cell lung cancer. Jpn J Clin Oncol 2008, 38:92-98. 10.1093/jjco/hym159, 18267986.
16. Xie SX, Li WX, Zeng ZJ, Chen YR. Escalated Dose Trial with Hypofractionated Three-dimensional Conformal Radiation Therapy for Non-small Cell Lung Cancer. Chin J Clin Oncol 2009, 36:972-975. (in Chinese).
17. Zhu GY, Xia TY, Wang LH, Gao XS, Wang JJ, Li GF, Zhang FQ, Ma L, Li YX, Xu B. Consensus and controversies on delineation of radiotherapy target volume for patients with non-small cell lung cancer. Chin J Radiat Oncol 2008, 17:432-436. (in Chinese).
18. Lin Q, Liu Y, Wang N, Huang Y, Ge X, Ren X, Chen X, Hu J, Guo Z, Zhao Y, Asaumi J. A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer. J Radiat Res 2013, 54:126-134. 10.1093/jrr/rrs081, 3534282, 22988282.
19. Uitterhoeve AL, Belderbos JS, Koolen MG, Van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, González González D, Bartelink H. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer 2000, 36:592-600. 10.1016/S0959-8049(99)00315-9, 10738123.
20. Lin Q, Gao XS, Qiao XY, Zhou ZG, Zhang P, Chen K, Zhao YN, Asaumi J. Phase I trial of escalatingdose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. Acta Med Okayama 2008, 62:37-44.
21. Lin Q, Wang J, Liu Y, Su H, Wang N, Huang Y, Liu CX, Zhang P, Zhao Y, Chen K. High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: a feasibility study. Oncol Lett 2011, 2:669-674. 3406461, 22848247.
22. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004, 22:45-52.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
24. Fletcher GH. Clinical dose response curves of human malignant epithelial tumors. Br J Radiol 1973, 46:151.
25. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(7 Suppl 3):S94-100.
26. Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B. Toxicity and outcome results of RTOG 9311: a phase I-II dose escalation study using three-dimensional conformal radiation therapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005, 61:318-328. 10.1016/j.ijrobp.2004.06.260, 15667949.
27. Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63:324-333. 10.1016/j.ijrobp.2005.02.010, 16168827.
28. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, Yannakakis D. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 1996, 34:315-322. 10.1016/0360-3016(95)02102-7, 8567332.
29. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076. 10.1001/jama.2010.261, 2907644, 20233825.
30. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839. 10.1200/JCO.2006.07.5937, 17050868.
31. Thirion P, Holmberg O, Collins CD, O'Shea C, Moriarty M, Pomeroy M, O'Sullivan C, Buckney S, Armstrong J. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 2004, 71:163-166. 10.1016/j.radonc.2003.09.006, 15110449.
32. Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chen GY, Jiang GL, Wang LJ, Zhao S, Fu XL. A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 2011, 98:304-308. 10.1016/j.radonc.2011.01.022, 21345508.
33. Ohri N, Dicker AP, Lawrence YR. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys 2012, 83:385-393. 10.1016/j.ijrobp.2011.06.1990, 22265460.
34. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, Van de Vaart P, Price A, Van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C, EORTC LCG and RT Group Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43:114-121. 10.1016/j.ejca.2006.09.005, 17084621, EORTC LCG and RT Group.
35. Maguire J, McMenemin R, O'Rourke N. SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. J Clin Oncol 2011, 29(suppl; abstr 7039):462s.
36. Carruthers R, O'Rourke N, Mohammed N, Hicks J, Brisbane. Toxicity of hypofractionated accelerated radiotherapy concurrent with chemotherapy for non-small cell carcinoma of the lung. Clin Oncol (R Coll Radiol) 2011, 23:561-562.
37. Cho KH, Ahn SJ, Pyo HR, Kim KS, Kim YC, Moon SH, Han JY, Kim HT, Koom WS, Lee JS. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys 2009, 74:1397-1404. 10.1016/j.ijrobp.2008.10.020, 19117690.